Monod Bio
Seattle, US · Founded 2020 · Delaware corporation · 27 employees on LinkedIn
Monod Bio is a University of Washington spin-out that uses AI-powered de novo protein design to develop research-use-only tools and in vitro diagnostics. It operates in the life sciences and medical diagnostics sector.
Founders & leadership
Monod Bio was founded in 2020 by Daniel Adriano Silva Manzano, Alfredo Quijano Rubio, and Daniel Silva Manzano.
DA
Daniel Adriano Silva ManzanoCo-founder
AQ
Alfredo Quijano RubioCo-Founder, CSO, Board Observer
DS
Daniel Silva ManzanoCo-Founder, CEO, Board Member
GT
Greg TibbittsFractional CFO
DJ
Dave JohnsonNamed on SEC filing
DS
David ShoultzNamed on SEC filing
BM
Berta Melina CimlerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$30.2M disclosed across 2 rounds · 2021–2022
▶$24.2MraisedJun 2022 · 31 investors · BiotechnologyRule 506(b)
▶$24.2MraisedJun 2022 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alfredo Quijano RubioExecutive Officer
- Daniel Adriano Silva ManzanoExecutive Officer, Director
- Karan TakharDirector
- Dave JohnsonDirector
- Berta Melina CimlerDirector
- David A ShoultzExecutive Officer, Director
- Offering amount
- $26.3M
- Amount sold
- $24.2M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6MraisedDec 2021 · 27 investors · BiotechnologyRule 506(b)
▶$6MraisedDec 2021 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel Adriano Silva ManzanoExecutive Officer, Director
- Dave JohnsonDirector
- David ShoultzExecutive Officer, Director
- Alfredo Quijano RubioExecutive Officer
- Berta Melina CimlerDirector
- Offering amount
- $6.1M
- Amount sold
- $6M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Manifold7 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
TRACER5 shared keywordsTRACER offers customized data quality services and analysis, emphasizing precision and speed to support faster decision-making for clients.
Companies competing with Monod Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Monod Bio do?
- Monod Bio is a University of Washington spin-out that uses AI-powered de novo protein design to develop research-use-only tools and in vitro diagnostics. It operates in the life sciences and medical diagnostics sector.
- Who founded Monod Bio?
- Monod Bio was founded by Daniel Adriano Silva Manzano, Alfredo Quijano Rubio, Daniel Silva Manzano in 2020.
- How much funding has Monod Bio raised?
- Monod Bio has disclosed $30.2M raised across 2 rounds.
- Where is Monod Bio headquartered?
- Monod Bio is headquartered in Seattle, US.